This study reveals genetic and proteomic risk factors for delirium, offering insights into its etiology and potential ...

An experimental drug called enlicitide reduced levels of low-density lipoprotein (LDL), or “bad” cholesterol by almost 60% in ...

A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk ...

I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince. Thank you, Andrew. Good afternoon, and thank you for joining us ...

A new experimental daily pill, Enlicitide, has shown a significant reduction in bad cholesterol by up to 60 per cent in ...

A study announced that LDL cholesterol levels decreased by 58% in clinical trials with the new drug, a PCSK9 inhibitor. This ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, ...

Dr. Jennifer Adams, whose daughter was diagnosed at 18 months with PH1, calls Oxlumo a "life-changing medication." As a result, her daughter's "quality of life has improved, hospital visits were ...

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...

Genetic screening in 84,000 people found hundreds of undiagnosed FH cases, revealing missed risks and treatment gaps.

Piper Sandler analyst David Amsellem last night initiated coverage of Esperion (ESPR) with an Overweight rating and $9 price target The company’s ...

A new study from researchers at the University of Naples “Federico II” has found that people with lower levels of LDL ...